TY - JOUR
T1 - Cellular therapy updates in b‐cell lymphoma
T2 - The state of the car‐t
AU - Crees, Zachary D.
AU - Ghobadi, Armin
N1 - Funding Information:
Conflicts of Interest: Zachary D. Crees declares no relevant conflict of interest. Armin Ghobadi declares consulting and advisory board roles for Kite, a Gilead Company, Amgen, Atara, Wugen, and Celgene/BMS, and research funding from Kite, a Gilead Company, and Amgen.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Non‐Hodgkin Lymphoma accounts for >460,000 cases and >240,000 deaths globally and >77,000 cases and >20,000 deaths in the U.S. annually, with ~85% of cases being B‐cell malignancies. Until recently, patients with relapsed/refractory B‐cell lymphoma following standard chemotherapy in combination with anti‐CD20 monoclonal antibodies and autologous stem cell transplantation experienced a median overall survival (OS) of <6 months. However, with the approval of four different CD‐19 CAR‐T therapies between 2017 and 2021, approximately 60–80% of patients receiving CAR‐T therapy now achieve an objective response with >3 years median OS. Here, we review the current state of the art of CD19 CAR‐T therapies for B‐cell lymphomas, focusing on current updates in US FDA‐approved products, along with their associated efficacy and toxicities. Lastly, we high-light a selection of promising clinical developments in the field, including various novel strategies to increase CAR‐T therapy efficacy while mitigating toxicity.
AB - Non‐Hodgkin Lymphoma accounts for >460,000 cases and >240,000 deaths globally and >77,000 cases and >20,000 deaths in the U.S. annually, with ~85% of cases being B‐cell malignancies. Until recently, patients with relapsed/refractory B‐cell lymphoma following standard chemotherapy in combination with anti‐CD20 monoclonal antibodies and autologous stem cell transplantation experienced a median overall survival (OS) of <6 months. However, with the approval of four different CD‐19 CAR‐T therapies between 2017 and 2021, approximately 60–80% of patients receiving CAR‐T therapy now achieve an objective response with >3 years median OS. Here, we review the current state of the art of CD19 CAR‐T therapies for B‐cell lymphomas, focusing on current updates in US FDA‐approved products, along with their associated efficacy and toxicities. Lastly, we high-light a selection of promising clinical developments in the field, including various novel strategies to increase CAR‐T therapy efficacy while mitigating toxicity.
KW - Adoptive cell therapy
KW - Axicabtagene ciloleucel
KW - Brexucabtagene autoleucel
KW - B‐cell lymphoma
KW - CAR‐T cell
KW - Chimeric antigen receptor
KW - Cytokine release syndrome
KW - Immune effector cell‐associated neurotoxicity syndrome
KW - Lisocabtagene maraleucel
KW - Tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85117120029&partnerID=8YFLogxK
U2 - 10.3390/cancers13205181
DO - 10.3390/cancers13205181
M3 - Review article
C2 - 34680329
AN - SCOPUS:85117120029
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 20
M1 - 5181
ER -